Author of

• 11692

  +

  P2.10 - Poster Session 2 - Chemotherapy (ID 207)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11712

    +

    P2.10-020 - Dose escalation and pharmacokinetic study of carboplatin and pemetrexed for elderly patients with advanced non-squamous, non-small-cell lung cancer: Kumamoto Thoracic Oncology Study Group Trial 1002 (ID 1329)

    09:30 - 09:30  |  Author(s): K. Akaike
    • Abstract

    Background
    This study was designed to determine the recommended dose of carboplatin-pemetrexed in elderly(≧70 years old), chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer. Also, we measured the blood level of pemetrexed in order to explore significant factors associated with toxicity or efficacy.

    Methods
    The patients were treated with carboplatin and pemetrexed every three weeks from 4 to 8 cycles. The dose of the anticancer drug escalated according to protocol.

    Results
    Grade 3 infection was observed as DLT at a dose of carboplatin AUC 5 and pemetrexed 500 mg/m[2], and we determined this phase as a recommended dose. Overall response rate was 15.3%, and the disease control rate was 76.9% in all cases. The median duration of progression-free survival was 3.9 months. The AUC of pemetrexed was associated with hematotoxicity, but not the efficacy. We observed that renal dysfunction induced high blood concentration of pemetrexed.

    Conclusion
    The combination of carboplatin AUC5 and 500mg/m[2] of pemetrexed is promising for elderly chemo-naïve patients with advanced non-squamous NSCLC, but dose reduction of pemetrexed may be required for patients with renal dysfunction in further study.